Secukinumab in severe COVID-19 pneumonia: Does it have a clinical impact?
- PMID: 34029628
- PMCID: PMC8139439
- DOI: 10.1016/j.jinf.2021.05.011
Secukinumab in severe COVID-19 pneumonia: Does it have a clinical impact?
Conflict of interest statement
Declaration of Competing Interest None.
Comment on
-
IL-6 inhibition in the treatment of COVID-19: A meta-analysis and meta-regression.J Infect. 2021 May;82(5):178-185. doi: 10.1016/j.jinf.2021.03.008. Epub 2021 Mar 18. J Infect. 2021. PMID: 33745918 Free PMC article.
References
-
- Hasan M J. Tocilizumab in COVID-19 treatment: a cost-burden in low- and middle-income countries. Int J Health Life Sci. 2000;6(2) doi: 10.5812/ijhls.104480. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
